The estimated Net Worth of Animal Health Inc Elanco is at least $92.5 Thousand dollars as of 27 August 2021. Animal Elanco owns over 45,508,938 units of Kindred Biosciences Inc stock worth over $92,500 and over the last 3 years Animal sold KIN stock worth over $0.
Animal has made over 1 trades of the Kindred Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Animal bought 45,508,938 units of KIN stock worth $420,957,677 on 27 August 2021.
The largest trade Animal's ever made was buying 45,508,938 units of Kindred Biosciences Inc stock on 27 August 2021 worth over $420,957,677. On average, Animal trades about 45,508,938 units every 0 days since 2021. As of 27 August 2021 Animal still owns at least 10,000 units of Kindred Biosciences Inc stock.
You can see the complete history of Animal Elanco stock trades at the bottom of the page.
Animal's mailing address filed with the SEC is 2500 INNOVATION WAY, , GREENFIELD, IN, 46140.
Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park, and Ernest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
Kindred Biosciences Inc executives and other stock owners filed with the SEC include: